T cell lymphoma
Conditions
Interventions
1:Dose group 1: azacitidine 50mg/m2, iv, d1-7
Chidamide 20mg, po, biw, taking the medicine for 3 weeks
4 weeks as a cycle
2:Dose group 2: azacitidine 75mg/m2, iv, d1-7
3:Dose group 3: azacitidine 50mg/m2, iv, d1-7
Chidamide 30mg, po, biw, taking the medicine for 3 weeks
4:Dose group 4: Azacytidine 75mg/m2, iv, d1-7
5:RP2D
Sponsors
Tianjin Cancer Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; ECOG score =100g/L, absolute neutrophil count >=1.5x10^9/L, platelets >=80x10^9/L, ALT, AST=1.5 ULN, serum albumin >=30g/L; 6. With at least one measurable lesion; 7. Without other serious diseases that conflict with this plan, and the cardiopulmonary function is basically normal; 8. Women of childbearing age must have a negative urine or blood pregnancy test, and male patients must use contraception during medication; 9. Without other anti-tumor concomitant therapy, but bisphosphonate anti-bone metastasis therapy and other symptomatic treatments can be applied; 10. Those who can understand the situation of this research and voluntarily sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic to the drugs in this plan; 2. Those who refuse to take reliable contraceptive measures during pregnancy, lactation or age; 3. Those who have any uncontrollable medical diseases (including uncontrolled diabetes, severe heart, lung, liver, and kidney insufficiency); 4. Accompanied by severe infection; 5. People with primary or secondary central nervous system tumor invaders; 6. Those who have chemotherapy contraindications; 7. Known active period of HBV or HCV infection (HBV virus copy number >=2x103IU/mL; HCV virus copy number >=103IU/mL); 8. Known HIV positive or HIV-related malignant tumors; 9. Those who take drugs or long-term alcoholism that affect the evaluation of test results; 10. People with peripheral nervous system disorders or mental disorders; 11. Those who are incapable of legal conduct, and those whose medical or ethical reasons affect the continuation of research; 12. Participate in other clinical research at the same time; 13. Combine anti-tumor drugs outside the research protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RP2D;MTD; | — |
Countries
China
Contacts
Public ContactZhang Huilai
Tianjin Cancer Hospital
Outcome results
None listed